Terms: = Uterine cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Prognosis
174 results:
1. FOXO3a deregulation in uterine smooth muscle tumors.
de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
[TBL] [Abstract] [Full Text] [Related]
2. Targeting her2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF; D'Souza A; Bello Roufai D; Tinker AV; de Miguel M; Gambardella V; Goldman J; Loi S; Melisko ME; Oaknin A; Spanggaard I; Shapiro GI; ElNaggar AC; Panni S; Ravichandran V; Frazier AL; DiPrimeo D; Eli LD; Solit DB
Gynecol Oncol; 2024 Feb; 181():162-169. PubMed ID: 38211393
[TBL] [Abstract] [Full Text] [Related]
3. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with her2 expression.
Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
[TBL] [Abstract] [Full Text] [Related]
4. Invasive stratified mucin-producing carcinoma (ISMC) of the cervix: a clinicopathological and molecular analysis of 59 cases with special emphasis on histogenesis and potential therapeutic targets.
Yao Y; Wang Y; Ye L; Lu B; Lu W
Histopathology; 2024 Jan; 84(2):315-324. PubMed ID: 37735961
[TBL] [Abstract] [Full Text] [Related]
5. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract] [Full Text] [Related]
6. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in uterine Serous Carcinoma.
Mutlu L; Manavella DD; Bellone S; McNamara B; Harold JA; Mauricio D; Siegel ER; Buza N; Hui P; Hartwich TMP; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner ES; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
Mol Cancer Ther; 2023 Dec; 22(12):1404-1412. PubMed ID: 37676984
[TBL] [Abstract] [Full Text] [Related]
7. her-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
[TBL] [Abstract] [Full Text] [Related]
9. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract] [Full Text] [Related]
10. Epidemiology of cervical cancer in elderly women: Analysis of incidence, treatment, and survival using German registry data.
Neumeyer S; Tanaka LF; Liang LA; Klug SJ
Cancer Med; 2023 Aug; 12(16):17284-17295. PubMed ID: 37403686
[TBL] [Abstract] [Full Text] [Related]
11. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
Li J; Xue X; Zhang Y; Ding F; Wu W; Liu C; Xu Y; Chen H; Ou Q; Shao Y; Li X; Wu F; Wu X
Gynecol Oncol; 2023 Aug; 175():133-141. PubMed ID: 37356314
[TBL] [Abstract] [Full Text] [Related]
12. Distinct histological and clinical features associated with pure uterine serous carcinoma: A single institution experience.
Zhi W; Zhan Y; He C; Jin Y
Ann Diagn Pathol; 2023 Oct; 66():152173. PubMed ID: 37352704
[TBL] [Abstract] [Full Text] [Related]
13. Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive cancers: Breast cancer, Cervical cancer, Endometrial cancer, Ovarian cancer and Prostate cancer.
Korbecki J; Bosiacki M; Barczak K; Łagocka R; Brodowska A; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108425
[TBL] [Abstract] [Full Text] [Related]
14. her2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Bruce SF; Wu S; Ribeiro JR; Farrell A; Oberley MJ; Winer I; Erickson BK; Klc T; Jones NL; Thaker PH; Powell MA
Gynecol Oncol; 2023 May; 172():98-105. PubMed ID: 37003074
[TBL] [Abstract] [Full Text] [Related]
15. Mixed mucinous adenocarcinoma/large cell neuroendocrine carcinoma of the uterine cervix: case report and molecular characterization of a rare entity.
Fattorini C; Rocca BJ; Giusti A; Arganini M; Perotti B; Cavazzana A; Ambrosio MR; Volante M
Virchows Arch; 2024 Jan; 484(1):141-146. PubMed ID: 36988712
[TBL] [Abstract] [Full Text] [Related]
16. Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of uterine Carcinosarcoma and Its Association with Clinical Efficacy.
Yagishita S; Nishikawa T; Yoshida H; Shintani D; Sato S; Miwa M; Suzuki M; Yasuda M; Ogitani Y; Jikoh T; Yonemori K; Hasegawa K; Hamada A
Clin Cancer Res; 2023 Jun; 29(12):2239-2249. PubMed ID: 36976261
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The cancer Genome Atlas-like Prognostic Subgroups.
Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
[TBL] [Abstract] [Full Text] [Related]
18. Assessment of her2 in Gastric-Type Endocervical Adenocarcinoma and its Prognostic Significance.
Wang S; Zhou X; Niu S; Chen L; Zhang H; Chen H; Zhou F
Mod Pathol; 2023 Jun; 36(6):100148. PubMed ID: 36841435
[TBL] [Abstract] [Full Text] [Related]
19. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
[TBL] [Abstract] [Full Text] [Related]
20. Ki67 and E-cadherin Are Independent Predictors of Long-term Survival in Endometrial Carcinoma.
Martin-Salamanca B; Erasun D; Llorca J; Schneider J
Anticancer Res; 2023 Feb; 43(2):683-687. PubMed ID: 36697084
[TBL] [Abstract] [Full Text] [Related]
[Next]
